Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy
Prevalence of anxiety or depression was investigated in 105 coronavirus disease 2019 (COVID‐19) patients at 1 to 3 months from virological clearance by hospital anxiety and depression scale (HADS‐A/D). 30% of patients displayed pathological HADS‐A/D, 52.4% showed persistent symptoms. Pathological pa...
Saved in:
| Published in: | Journal of medical virology Vol. 93; no. 2; pp. 1175 - 1179 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
01.02.2021
John Wiley and Sons Inc |
| Subjects: | |
| ISSN: | 0146-6615, 1096-9071, 1096-9071 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Prevalence of anxiety or depression was investigated in 105 coronavirus disease 2019 (COVID‐19) patients at 1 to 3 months from virological clearance by hospital anxiety and depression scale (HADS‐A/D). 30% of patients displayed pathological HADS‐A/D, 52.4% showed persistent symptoms. Pathological patients with HADS‐A/D more commonly reported symptom persistence, even after adjustment for age, gender, and disease severity. Psychological assessments should be encouraged in COVID‐19 patients' follow‐up.
Highlights
1‐3 months after clinical and virological recovery from symptomatic COVID‐19 disease, 30% and 52.4% of patients still presented psychological and physical symptoms, respectively
Persistence of anxiety and depression was independently associated with ongoing physical symptoms
Psychological evaluations should be included in the follow‐up of COVID‐19 patients. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ISSN: | 0146-6615 1096-9071 1096-9071 |
| DOI: | 10.1002/jmv.26459 |